|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Instruments for evaluating nurse competence显示文摘 | Meretoja R Leino-Kilpi H | | 0，，7： | 1 |
| 2 | A systematic model to compare nurses' optimal and actual competencies in the clinical setting显示文摘 | Meretoja R Koponen L | 2011 | Journal of Advanced Nursing2011，68，2： | 1 |
| 3 | Off-label thrombolysis isnot associated with poor outcome in patients with stroke显示文摘 | Meretoja A Putaala J Tatlisumak T | 2010 | Stroke2010，41，7： | 1 |
| 4 | Sevoflurane-nitrous oxide or hal- othane-nitrous oxide for paediatric bronchoscopy and gastroscopy 显示文摘 | Meretoja OA Taivainen T Raiha L | 1996 | Br J Anaesth1996，76，6： | 1 |
| 5 | Dose-response and time-course of effect of rocuronium bromide in paediatric patients显示文摘 | Meretoja OA Taivainen T Erkola O | 1995 | Eur J Anaesth1995，12，11： | 1 |
| 6 | Patientoutcomes from symptomatic intracerebral hemorrhage afterstroke thrombolysis显示文摘 | STRBIAN D SAIRANEN T MERETOJA A | 2011 | Neurology2011，77，4： | 1 |
| 7 | Late results of skin- sparing mastectomy followed by immediate breast reconstruction 显示文摘 | Meretoja TJ Rasia S yon Smitten KA | 2007 | BrJSurg2007，94，10： | 1 |
| 8 | Enhancing chondrogenic phenotype for cartilage tissue engineering= rnonoculture and coculture of articular chondrocytes and rnesenehymal stem cells显示文摘 | Hubka KM Dahlin RL Meretoja VV | 2014 | Tissue Eng Part B Rev2014，20，6： | 1 |
| 9 | Reducingin-hospital delay to 20 minutes in stroke thrombolysis显示文摘 | MERETOJA A STRBIAN D MUSTANOJA S | 2012 | Neurology2012，79，4： | 1 |
| 10 | Enhanced ehondrogene- sis in co-cultures with articular ehondrocytes and mesenchymal stem cells 显示文摘 | Meretoja Dahlin RL Kasper FK | 2012 | Biomaterials2012，33，27： | 1 |
| 11 | Post-thrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke 显示文摘 | PUTAALA J SAIRANEN T MERETOJA A | 2011 | Cerebrovasc Dis2011，31，1： | 1 |
| 12 | Nurse Competence Scale: Development and Psychometric Testing显示文摘 | Meretoja R Isoabo H Leino-Kilpi H | 2004 | J Adv Nurs2004，47，2： | 1 |
| 13 | International muhi- center tool to predict the risk of nonsentinel node metastases in breast cancer显示文摘 | Meretoja TJ Leidenius MH Heikkila PS | 2012 | J Nail Cancer Inst2012，104，24： | 1 |
| 14 | Outcome of oncoplasticbreast surgery in 90 prospective patients 显示文摘 | Meretoja TJ Svarvar C Jahkola TA | 2010 | Am J Surg2010，200，2： | 1 |
| 15 | Sevoflurane-nitrous Oxide or halothane-nitrous oxide for paediatric bronehoseopy and gastroscopy显示文摘 | Meretoja OA Taivainen T Raiha L el a1 | 1996 | Br J Anaesth1996，，76： | 1 |
| 16 | Neuromuscular block and current treatment strategies for its reversal in children显示文摘 | Meretoja O A | 2010 | Paediatr Anaesth2010，20，7： | 1 |
| 17 | Reducing in-hospitaldelay to 20 minutes in stroke thrombolysis显示文摘 | Meretoja A Strbian D Mustanoja S | 2012 | Neurology2012，79，4： | 1 |
| 18 | Reducing in-hospital delay to 20 minutes in stroke thrombolysis显示文摘 | Meretoja A Strbian D Mustanoja S | 2012 | Neurology2012，79，4： | 1 |
| 19 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 20 | Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score显示文摘 | Strbian D Meretoja A Ahlhelm FJ | 2012 | Neurology2012，78，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员